Tvardi Therapeutics (TVRD) Stock Analysis

What Tvardi Therapeutics does

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Key metrics

ETFs linked to TVRD

Broad-market and Healthcare sector ETFs an investor holding Tvardi Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TVRD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Tvardi Therapeutics?

Tvardi Therapeutics trades under the ticker TVRD on NASDAQ.

Which exchange is TVRD listed on?

TVRD is listed on NASDAQ.

What sector does Tvardi Therapeutics operate in?

Tvardi Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TVRD in a portfolio?

PortView shows TVRD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.